SPORE in Brain Cancer

脑癌中的孢子

• 批准号: 7432340
• 负责人: W K ALFRED Yung
• 金额: $ 230万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-01 至 2013-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7432340
• 关键词: SPORE; Brain; Cancer

DESCRIPTION (provided by applicant): The objective of The University of Texas M. D. Anderson Cancer Center (UTMDACC) SPORE in Brain Cancer is to develop a robust translational research program with an emphasis on innovative treatments based on combinations of agents, molecularly-based diagnosis, and therapy monitoring, through which significant impact on the care of patients with malignant brain tumors will be achieved. UTMDACC has established the elimination of brain tumors as a priority and has made significant investments in this goal through establishment of a Brain Tumor Center and a Multidisciplinary Research Program to support training and research across several departmental boundaries, including neuro-oncology, neuro-surgery, neuro-pathology, diagnostic imaging, radiation oncology, epidemiology, molecular therapeutics, molecular genetics, molecular biology, pediatrics, and statistics. With this support, we have successfully organized an efficient and productive infrastructure that forms the basis for this SPORE. The translational research in this application is based on recent insights into the molecular basis of brain tumors and aims to translate these findings into innovative approaches to improve molecular diagnosis so that patients receive the therapy most likely to be benefit them, permit early evaluation of response to targeted treatment, and establish new and effective treatments based on oncolytic viruses and small molecule signal transduction inhibitors. The focus of the four Projects is described below: Project 1: Test a targeted oncolytic adenovirus, Delta-24-RGD in the clinic, and improve it by combining it with temozolomide and by delivery with mesenchymal stem cells. Project 2: Test PI3K inhibitor PX-866 in the clinic and develop rational combination therapies based on it. Project 3: Develop a molecular biomarker panel capable of identifying patients not likely to benefit from standard therapy, test it in the RTOG-0525 clinical trial with over 800 patients, and identify novel targets in the treatment of resistant tumors to support new therapy development. Project 4: Explore genetic predictors of neurocognitive and clinical outcome in glioblastoma patients. Five Cores (Administrative, Pathology and Tissue Procurement, Biostatistics, Clinical and Animal) will support the Projects, Career Development Program, and Developmental Research Program. It is imperative that we aggressively undertake translational research, as is embodied in this proposal to develop more effective approaches for patients with brain cancer; there are no effective treatment approaches for this patient population, and this SPORE guarantees that all of the resources of the UTMDACC Brain Tumor Research Program, as well as the considerable resources of the entire institution, will be brought to bear on this important public health problem.

描述（由申请人提供）：德克萨斯大学M. D. Anderson癌症中心（UTMDACC）在脑癌中的目的是制定一项健壮的翻译研究计划，重点是基于基于药剂组合，基于分子的诊断和治疗的创新治疗，并通过对脑部肿瘤的患者进行严重影响，从而有效地影响。 UTMDACC has established the elimination of brain tumors as a priority and has made significant investments in this goal through establishment of a Brain Tumor Center and a Multidisciplinary Research Program to support training and research across several departmental boundaries, including neuro-oncology, neuro-surgery, neuro-pathology, diagnostic imaging, radiation oncology, epidemiology, molecular therapeutics, molecular genetics, molecular生物学，儿科和统计。在这种支持下，我们成功地组织了一个高效且生产性的基础设施，构成了该孢子的基础。本应用中的翻译研究基于对脑肿瘤分子基础的最新见解，并旨在将这些发现转化为改善分子诊断的创新方法，以便患者最有可能受益于他们的疗法，允许对靶向治疗的反应进行早期评估，并基于On -Colytic病毒和小分子信号转移者进行新的和有效的治疗。这四个项目的重点如下： 项目1：在诊所中测试靶向溶瘤腺病毒，Delta-24-RGD，并通过将其与替莫唑胺结合并与间充质干细胞递送来对其进行改进。 项目2：在诊所中测试PI3K抑制剂PX-866，并基于IT开发理性组合疗法。 项目3：开发一个能够鉴定出不太可能从标准疗法中受益的患者，在RTOG-0525临床试验中对其进行测试的分子生物标志物面板，并在800多名患者中进行了测试，并确定了耐药性肿瘤以支持新疗法开发的新靶标。 项目4：探索胶质母细胞瘤患者神经认知和临床结果的遗传预测因子。五个核心（行政，病理和组织采购，生物统计学，临床和动物）将支持项目，职业发展计划和发展研究计划。我们必须积极进行转化研究，这是该提案所体现的，以开发为脑癌患者开发更有效的方法。该患者人群没有有效的治疗方法，该孢子可以保证UTMDACC脑肿瘤研究计划的所有资源以及整个机构的大量资源都将被带来这一重要的公共卫生问题。